Glenmark Pharmaceuticals has initiated the process of reorganising itself into three different entities and expects the process to be completed in the current fiscal year.
This reorganisation is designed to place Glenmark on an accelerated trajectory and these three different entities will together make up the Glenmark group of companies.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).